Synopsis: Based on DESTINY-Breast04 results which showed Daiichi Sankyo and AstraZeneca’s ENHERTU reduced risk of disease progression or death by 50% and…
Tag:
Enhertu
-
-
Daiichi SankyoRegulatoryU.S FDA
FDA Grants Regular Approval to Fam-Trastuzumab Deruxtecan-Nxki(Enhertu) for Breast Cancer
by adminby adminSummary: Food and Drug Administration approved fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) for adult patients with unresectable or metastatic HER2-positive breast cancer…
-
Patent LitigationPatents
Seagen Scores $41.8M in Enhertu Patent Case Against Daiichi Sankyo
by adminby adminSummary : A federal jury has awarded biotechnology company Seagen Inc. $41.8 million in a patent infringement lawsuit against Daiichi Sankyo Co.…
-
AgrochemicalsGlobal Market
Daiichi Sankyo Starts Patient dosing in DESTINY-Lung04 Phase 3 trial of Enhertu
by adminby adminSummary : Daiichi Sankyo Company, Limited announced that the first patient was dosed in the global DESTINY-Lung04 phase 3 trial evaluating the…